Literature DB >> 8762991

[Additional supra-malleolar osteotomy].

P Vichard1, E Gagneux, P Garbuio, B E Elias.   

Abstract

This old operation is rarely practiced and it appeared interesting to precise its technique and indications from a short series. In the majority of our cases, a valgus type osteotomy by medial graft addition was performed. One or more prismatic triangular graft are taken from the full thickness of the iliac crest. The respect of the fibula protects the periostal hinge on the other side of the surgical approach; so the graft under pressure will have rapid and constant consolidation. Tibial osteosynthesis is facultative. We can distinguish major indications of that type of osteotomies: supramalleolar malunion, while the fracture of the fibula associated to the tibia is a contra-indication for that operation. The other indications are the distortion of the pilon articular surface and old ligamentous lesions leading to osteoarthritis. In some cases, it is appropriate to realise valgisation of the articular surface, with an overcorrection to harmonise the pressure on articular surfaces; on that condition, an osteotomy of the fibula has to be discussed. The rapid and constant good results obtained with those iliac crest grafts interposed between the two fragments of the tibia contrast with those hazardous results of inlay or onlay grafts, free from all mecanical sollicitations.

Entities:  

Mesh:

Year:  1996        PMID: 8762991

Source DB:  PubMed          Journal:  Rev Chir Orthop Reparatrice Appar Mot        ISSN: 0035-1040


  2 in total

1.  Tricortical bone grafts for treatment of malaligned tibias and fibulas.

Authors:  Joseph Borrelli; Stéphane Leduc; Ronald Gregush; William M Ricci
Journal:  Clin Orthop Relat Res       Date:  2009-01-15       Impact factor: 4.176

2.  Arthroscopic evaluation of persistent pain following supramalleolar osteotomy for varus ankle osteoarthritis.

Authors:  Yong Sang Kim; Hyun Kook Youn; Bom Soo Kim; Yun Jin Choi; Yong Gon Koh
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-07-30       Impact factor: 4.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.